278 results Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business. Stibbe advises Warner Music Group Stibbe advises Warner Music Group on its acquisition of Spinnin’ Records. Stibbe advises Aedifica Stibbe advised Aedifica recently on two transactions in order to further expand her Dutch portfolio of care assets. Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of a care residence that will be constructed in Leersum. Aedifica acquired the full property of the site from Woudenburcht B.V., a local real estate developer. See for the press release here. Stibbe advises Moody’s Corporation Stibbe is advising Moody’s Corporation, the US credit rating agency, on its € 3 billion acquisition of Bureau van Dijk, a global provider of business intelligence and company information, from Swedish private equity firm EQT. Stibbe represents Simed in dispute with Slotervaart hospital Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b Stibbe advises financial sector IT services supplier Advising a financial sector supplier of cashless transaction technologies and IT services on various contractual and regulatory issues, including those related to data center activities. Stibbe advises UPS Stibbe advises an absence administration company Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products. Stibbe advises confidential client Stibbe advises SCA Hygiene Products Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding. Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products. Stibbe advises on the contemplated IPO of Agendia Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products. Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency. Stibbe advises on the IPO of Tornier Pagination Previous page Page 13 Page 14 Current page 15 Page 16 Next page
Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.
Stibbe advises Warner Music Group Stibbe advises Warner Music Group on its acquisition of Spinnin’ Records.
Stibbe advises Aedifica Stibbe advised Aedifica recently on two transactions in order to further expand her Dutch portfolio of care assets.
Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of a care residence that will be constructed in Leersum. Aedifica acquired the full property of the site from Woudenburcht B.V., a local real estate developer. See for the press release here.
Stibbe advises Moody’s Corporation Stibbe is advising Moody’s Corporation, the US credit rating agency, on its € 3 billion acquisition of Bureau van Dijk, a global provider of business intelligence and company information, from Swedish private equity firm EQT.
Stibbe represents Simed in dispute with Slotervaart hospital Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b
Stibbe advises financial sector IT services supplier Advising a financial sector supplier of cashless transaction technologies and IT services on various contractual and regulatory issues, including those related to data center activities.
Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products.
Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding.
Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.
Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.
Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency.